HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
An FDA advisory panel recommended Replimune's experimental melanoma drug RP1 after a 10-3 vote, but the weight loss drug market shows signs of slowing as employers and insurers reduce coverage. The FDA's new leadership is being observed for its approach to evaluating investigational drugs.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
- STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
- STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
- STAT+: Pharmalittle: We’re reading about another FDA reversal, pharma’s M&A spree and much more
- STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment